Rich Shea | RNA Aptamer Technology and Innovation in Acute Thrombosis Treatment
Rich Shea joins Executive Insights for Life Sciences Innovators to discuss RNA therapeutics, acute thrombosis treatment, and the development of innovative technologies designed to address critical cardiovascular conditions.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Rich Shea discusses how Basking Biosciences is advancing RNA aptamer technology for the treatment of acute thrombosis. The conversation explores the scientific potential of RNA-based therapeutics, the challenges of developing novel cardiovascular treatments, and the strategic decisions involved in building biotechnology companies around emerging platform technologies.
Key Themes
- RNA aptamer technology and therapeutic innovation
- Acute thrombosis treatment and cardiovascular medicine
- Next-generation RNA-based therapeutics
- Translating breakthrough science into clinical development
- Building biotechnology companies around platform technologies
- Innovation in cardiovascular drug development
Why This Matters for Life Sciences Leaders
Cardiovascular disease remains one of the leading causes of morbidity and mortality worldwide, creating ongoing demand for more effective and targeted treatment approaches. The conversation highlights how emerging RNA technologies may offer new therapeutic possibilities while illustrating the scientific, operational, and commercial challenges of advancing innovative therapies from concept to clinic.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
